These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38649158)

  • 21. A real-world analysis of roxadustat effectiveness and safety in managing renal anemia among patients on maintenance hemodialysis: An observational study.
    Zhang Y; Chen M; Tang L; Chen X; Meng Y; Feng S
    Medicine (Baltimore); 2024 Aug; 103(31):e39203. PubMed ID: 39093766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis.
    Wu T; Qi Y; Ma S; Zhang L; Pu X; Chen K; Zhao Y; Sang S; Xiao J
    Ren Fail; 2022 Dec; 44(1):529-540. PubMed ID: 35318873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis.
    Jin C; Ren Y; Wang M; Hu X; Shang Y; Li Y; Zhu B; He Q; Shao L
    Int Urol Nephrol; 2024 Aug; 56(8):2683-2693. PubMed ID: 38489143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study.
    Bao L; Bian X; Zhang A; Huang J; Ren L; Luo C
    Ann Palliat Med; 2022 Jun; 11(6):2017-2024. PubMed ID: 35817736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical efficacy of combined ESA and Roxadustat treatment for renal anemia in hemodialysis patients with secondary hyperparathyroidism: A case series.
    Zhong JJ; Wang ML; Zheng GF; Li MP; Chen DZ
    Medicine (Baltimore); 2024 Aug; 103(33):e39083. PubMed ID: 39151521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of roxadustat in maintenance hemodialysis patients with erythropoietin-hyporesponsive anemia.
    Wang X; Cai H; Xu H; Chen L
    Clin Nephrol; 2024 Jan; 101(1):25-33. PubMed ID: 37969110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of roxadustat to erythropoiesis-stimulating agent (ESA) effectively corrects ESA-hyporesponsive anaemia in patients on peritoneal dialysis.
    Dai S; Chen Y; Hao C; Ge X; Xie Q; Shang D; Zhu T
    J Clin Pharm Ther; 2022 Oct; 47(10):1525-1530. PubMed ID: 35633100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
    Mima A; Horii Y
    In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
    Yang X; Zhao B; Wang J; Wang L; Tao M; Lu J; Lin J; Sun J; Wang R
    Ren Fail; 2021 Dec; 43(1):1428-1436. PubMed ID: 34657570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.
    Luo X; Li G; Yang H; Chen L; Gao Y; Cong J; Luo H; Zhang W
    BMC Nephrol; 2024 Feb; 25(1):47. PubMed ID: 38311719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation.
    Zhou Y; Chen XX; Zhang YF; Lou JZ; Yuan HB
    Intern Emerg Med; 2021 Nov; 16(8):2193-2199. PubMed ID: 34021853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
    Zhang L; Hou J; Li J; Su SS; Xue S
    Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roxadustat Versus Erythropoietin: The Comparison of Efficacy in Reversing Ventricular Remodeling in Dialysis Patients with Anaemia.
    Wang MY; Liu XQ; Jiang TT; Liu WT; Huang Y; Huang YL; Jin FY; Zhao Q; Wu QY; Wang GH; Ruan XZ; Ma KL
    Int J Med Sci; 2024; 21(4):703-713. PubMed ID: 38464833
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative analysis of roxadustat efficacy between maintenance hemodialysis and peritoneal dialysis patients.
    Zhang L; Huang Y; Yin D; Zhu T; Liu Q; Li Y; Gan L
    Clin Nephrol; 2024 Jan; 101(1):34-42. PubMed ID: 37877297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.